CymaBay Terminates Phase 2B Study of Seladelpar in NASH
December 5, 2019 Impact: High CymaBay Therapeutics has terminated its phase 2b study of PPARδ agonist, seladelpar, in patients with NASH due to atypical histological findings. Planned, blinded histological assessments of liver biopsies from trial participants revealed histology characterized as an interface hepatitis presentation, with or without biliary injury. Notably, the atypical histological findings were […]